Replies to post #77957 on Biotech Values

[DewDiligence]

ISRG: I'm not sure that number was disclosed.

If the procedure count is the metric of all metrics by which investors should be evaluating ISRG’s business, doesn’t it seem odd that this isn’t disclosed on a quarterly basis?

There are some modest seasonal effects in procedure numbers, so I still think YoY provides more information than sequential.

I strenuously disagree and I thought we had resolved this in a prior thread. If there’s any seasonal effect worth talking about, it’s in Q3, which is the summer vacation period in the Northern hemisphere. There should be no seasonal slowdown whatsoever in Q1, so it makes perfect sense to compare the 1Q09 procedure count to the 4Q08 procedure count.

The fact that ISRG will not disclose either the procedure count in 1Q09 or the quarter-over-quarter change from 4Q08 to 1Q09 strongly suggests that the procedure count did not grow on a quarter-over-quarter basis. If I were long this stock, I would sure as heck want to know why.

[corpstrat]

<<There are ~650,000 hysterectomies carried out each year in the U.S. alone.>>

Until Proellex is approved. You might want to hedge your ISRG with a little RPRX. (Hey it's a quiet weekend.)